No­var­tis builds its case for a new sick­le cell drug, eye­ing a de­layed FDA fil­ing in ‘19

Re­searchers at No­var­tis have tak­en an­oth­er crack at the da­ta they col­lect­ed in a Phase II study of their sick­le cell dis­ease drug crizan­l­izum­ab, build­ing their case ahead of a loom­ing reg­u­la­to­ry fil­ing.

Check­ing on the rate of dis­ease-re­lat­ed pain crises among pa­tients, No­var­tis scored their drug with 35.8% of the pa­tients on drug avoid­ing a cri­sis dur­ing the pre­vi­ous year. That’s more than twice the 16.9% rate tracked in the place­bo arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER